Harbour Antibodies

📍 Newton, United States🗓 Founded 2006💰 Last funded Jan 2007
Biotechnology🌐 harbourantibodies.com
Website LinkedIn
Harbour Antibodies BV was established in 2006 to use transgenic mouse technology developed in the laboratory of Professor Frank Grosveld at Erasmus MC (Rotterdam, the Netherlands) for engineering mice to produce high affinity human antibodies. A fully owned subsidiary of Harbour BioMed, Harbour Antibodies owns two strains of transgenic mice for generating human therapeutic antibodies: 1) H2L2: Mice that generate antibodies comprised of two heavy chain and two light chains (H2L2) with fully human variable regions. 2) HCAb: Mice that generate novel “heavy chain only” antibodies (HCAb). The HCAb mice enable the development of antibody fragment-based therapeutics such as nanobodies, bi-specific antibodies and CAR-T with favorable drug-like properties. For additional information and Out-Licensing: Please visit http://harbourantibodies.com -or- email contact@harbourbiomed.com
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2006
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Harbour Antibodies?
Harbour Antibodies has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Harbour Antibodies last raise funding?
The most recent investment in Harbour Antibodies recorded on gritt.io was in January 2007.
When was Harbour Antibodies founded?
Harbour Antibodies was founded in 2006.
What industry is Harbour Antibodies in?
Harbour Antibodies operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Harbour Antibodies based?
Harbour Antibodies is headquartered in Newton, United States.